Form 4: Liquidia CBO Jason Adair Granted Equity Awards

Liquidia Corporation's Chief Business Officer, Jason Adair, was granted 27,683 Restricted Stock Units and 41,525 Performance Stock Units on January 16, 2026.

Summary

• Jason Adair, Chief Business Officer of Liquidia Corp (LQDA), was granted equity awards on January 16, 2026.
• The awards include 27,683 Restricted Stock Units (RSUs) and 41,525 Performance Stock Units (PSUs).
• RSUs convert into common stock on a one-for-one basis and vest 25% on January 11, 2027, with 6.25% vesting every three months thereafter.
• PSUs also convert into common stock on a one-for-one basis and vest 25% on January 11, 2027 (or later, upon FY2026 10-K filing), with 6.25% vesting every three months, subject to a milestone-based condition.
• The milestone for PSU vesting is based on net product sales revenue from YUTREPIA in 2026, as disclosed in the Issuer's FY2026 10-K.
• Following these transactions, Jason Adair beneficially owns 211,857 shares of common stock (including unvested RSUs and ESPP shares) and 41,525 PSUs.

Sentiment

Score: 7

Explanation: The grant of significant equity awards to a key executive is generally a positive signal, indicating continued commitment, retention, and alignment of interests with shareholders. The performance-based vesting for PSUs further incentivizes the executive to drive product sales, which is beneficial for the company. However, it's a routine compensation event rather than a major strategic announcement.

Positives

• Grant of 27,683 Restricted Stock Units (RSUs) to the Chief Business Officer, aligning management's interests with shareholder value.
• Grant of 41,525 Performance Stock Units (PSUs) to the Chief Business Officer, which are tied to the achievement of net product sales revenue from YUTREPIA in 2026, incentivizing performance.
• The equity grants demonstrate continued commitment and retention of key executive talent.

Risks

• The full realization of the Performance Stock Units (PSUs) by the Chief Business Officer is contingent upon achieving specific net product sales revenue from YUTREPIA in 2026, which introduces a performance-based challenge for the company to meet these sales targets.

Future Outlook

The vesting of 41,525 Performance Stock Units is tied to the achievement of net product sales revenue from YUTREPIA in 2026, as will be disclosed in the company's FY2026 Form 10-K. This indicates a strategic focus on YUTREPIA's commercial performance in the coming fiscal year.

Industry Context

This Form 4 filing details an individual executive's equity compensation, which is a standard practice across industries to incentivize and retain key personnel. The performance-based vesting tied to YUTREPIA sales suggests the company's strategic focus on the commercialization of this specific product, which is common in the pharmaceutical and biotechnology sectors where product launches and sales performance are critical drivers of value.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) as part of executive compensation is a common practice in the biotechnology and pharmaceutical industries, aligning with compensation structures seen at companies like United Therapeutics (UTHR) or Acceleron Pharma (acquired by Merck), where product development and commercialization milestones often dictate executive incentives.
• The specific vesting schedule, with an initial 25% vesting and quarterly increments, is a standard approach to ensure long-term retention and performance.
• Tying PSU vesting to net product sales revenue from a key product like YUTREPIA is a direct incentive mechanism, comparable to performance metrics used by companies such as Gilead Sciences for their HIV drug portfolio or Amgen for new oncology treatments, where sales targets are critical for executive bonuses and equity awards.

Stakeholder Impact

• Shareholders: The grants align the Chief Business Officer's interests with shareholder value, particularly through performance-based PSUs tied to YUTREPIA sales, potentially leading to increased long-term value if performance targets are met.
• Employees: This filing pertains to executive compensation and does not directly impact the broader employee base, though it reflects the company's compensation philosophy for key roles.
• Customers: The focus on YUTREPIA sales for PSU vesting suggests a continued emphasis on the product, which could benefit customers through sustained product availability and support.

Next Steps

• Vesting of 25% of RSUs on January 11, 2027, with subsequent quarterly vesting.
• Vesting of 25% of PSUs on January 11, 2027, or the date of the FY2026 10-K filing, contingent on YUTREPIA net product sales revenue in 2026.
• Subsequent quarterly vesting of 6.25% of PSUs following the initial vesting date, subject to the performance condition.
• Disclosure of YUTREPIA net product sales revenue for 2026 in the Issuer's FY2026 10-K.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a key executive, which is a standard compensation practice. It aligns management incentives with company performance, particularly for YUTREPIA sales, which is a positive for long-term shareholder value. However, it does not present new material information that would fundamentally alter the investment thesis or warrant a change in an existing position. It reinforces a 'hold' stance, acknowledging the ongoing efforts to incentivize leadership without providing a catalyst for immediate significant price movement.

Keywords

Liquidia Corp, LQDA, Jason Adair, Chief Business Officer, Restricted Stock Units, RSUs, Performance Stock Units, PSUs, Equity Grant, Insider Transaction, Executive Compensation, YUTREPIA, SEC Form 4